Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.74 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10047660 | 0.87 | FGFR1 (0.69) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL13799140 | 0.86 | FGFR1 (0.56) | FGFR1HPRT1 | |
| SCHEMBL13799134 | 0.86 | FGFR1 (0.56) | FGFR1HPRT1 | |
| SCHEMBL13825656 | 0.86 | FGFR1 (0.75) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| Cyclic Cidofovir SCHEMBL14461986 | 0.85 | FGFR1 (1.00) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| Cyclic Cidofovir SCHEMBL2380283 | 0.85 | FGFR1 (1.00) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| Cyclic Cidofovir SCHEMBL140858 | 0.85 | FGFR1 (1.00) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL14308878 | 0.85 | FGFR1 (0.71) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL13819331 | 0.85 | FGFR1 (0.70) | FGFR1HPRT1LMNAPDE3ACACNA1F | |
| SCHEMBL13799137 | 0.83 | FGFR1 (0.53) | FGFR1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | CHIMERIX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120164104-A1 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8063209-B2 | Phosphonyl ester conjugates as prodrugs | TSRL, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110263536-A1 | Methods of Treating Orthopox Virus Infections and Associated Diseases | CHIMERIX, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7994143-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| WO-2011053812-A1 | METHODS OF TREATING VIRAL ASSOCIATED DISEASES | CHIMERIX, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011017253-A1 | COMPOSITION AND METHODS OF TREATING VIRAL INFECTIONS AND VIRAL INDUCED TUMORS | CHIMERIX, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011011710-A1 | METHODS OF TREATING VIRAL INFECTIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011519-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7749983-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090270618-A1 | PHOSPHONYL ESTER CONJUGATES AS PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-29 | — | — | US | disclosed |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7511051-B2 | Cidofovir peptide conjugates as prodrugs | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-03-31 | — | — | US | disclosed |
| US-7439350-B2 | Nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | FGFR1 4116/4885HPRT1 411/4885LMNA 3859/4885 |
| US-20090270618-A1 | PHOSPHONYL ESTER CONJUGATES AS PRODRUGS | DNPEP, PHOSPHO1, TYMP | FGFR1 1739/4885HPRT1 185/4885LMNA 3367/4885 |
| US-20090149648-A1 | NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | FGFR1 2236/4885HPRT1 50/4885LMNA 1209/4885 |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | FGFR1 1923/4885HPRT1 1046/4885LMNA 2085/4885 |
| US-20110263536-A1 | Methods of Treating Orthopox Virus Infections and Associated Diseases | OAT, PNPO, OTC | FGFR1 4514/4885HPRT1 568/4885LMNA 4178/4885 |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | FGFR1 1036/4885HPRT1 183/4885LMNA 3293/4885 |
| US-20170333459-A1 | METHODS OF TREATING ORTHOPOX VIRUS INFECTIONS AND ASSOCIATED DISEASES | OAT, PNPO, OTC | FGFR1 4514/4885HPRT1 568/4885LMNA 4178/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | FGFR1 4116/4885HPRT1 411/4885LMNA 3859/4885 |
| US-20120164104-A1 | Composition and Methods of Treating Viral Infections and Viral Induced Tumors | HAVCR2, IRF3, CCL5 | FGFR1 1945/4885HPRT1 950/4885LMNA 4029/4885 |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | FGFR1 1036/4885HPRT1 183/4885LMNA 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.